Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane with or without Tigatuzumab in Metastatic TNBC
NCT01307891Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2011
- Primary completion
- Jun 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tigatuzumab in triple-negative breast cancer (TNBC), sponsored by University of Alabama at Birmingham. Started Mar 2011; status: completed.
02
Drugs
tigatuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01307891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307891.